Circulating concentrations of free triiodothyronine are associated with central adiposity and cardiometabolic risk factors in young euthyroid adults

Elisa Merchan-Ramirez · Guillermo Sanchez-Delgado · Cristina Arrizabalaga-Arriazu · Francisco M Acosta · Maria Jose Arias-Tellez · Manuel Muñoz-Torres · Jose V Garcia-Lario · Jose M Llamas-Elvira · Jonatan R Ruiz

Received: 9 July 2021 / Accepted: 18 February 2022 / Published online: 6 April 2022 © The Author(s) 2022

Abstract
Thyroid dysfunction is associated with classic cardiometabolic risk factors in humans. However, this relationship remains unclear in young euthyroid adults. The present work examines the associations of circulating thyroid hormones (THs) and thyroid-stimulating hormone (TSH) concentrations with body composition and cardiometabolic risk factors in young euthyroid adults. A total of 106 sedentary, euthyroid adults (72 women; 22 ± 2 years old) participated in this cross-sectional study. THs and TSH serum concentrations were determined in fasting conditions (6 h). Body composition (fat mass (FM), lean mass (LM), and visceral adipose tissue (VAT)) was determined by dual-energy X-ray absorptiometry, anthropometric parameters (weight, height, and waist circumference) were measured, and neck adipose tissue mass was quantified through computed tomography (CT) scanning. Cardiometabolic risk factors including fasting glucose and lipid metabolism markers, hepatic phosphatase and transaminases, and blood pressure were also assessed. Free triiodothyronine (FT3) concentration was positively associated with body mass index, LM, VAT, and waist circumference (all P ≤ 0.038). FT3 was also associated with glucose, insulin, HOMA-IR, fatty liver index, and blood pressure (all P < 0.024). All the associations were attenuated when adjusting for sex. In contrast, we found no associations of TSH or free thyroxine with any body composition parameter or cardiometabolic risk factors. In conclusion, FT3 is associated with central adiposity and cardiometabolic risk factors including insulin resistance, fatty liver index, and mean, systolic and diastolic blood pressure in young euthyroid adults. ClinicalTrials.gov identifier: NCT02365129.

Keywords Thyroid function · Body composition · Cardiometabolic risk factors · Obesity · Euthyroid

Abbreviations
ALP  Alkaline phosphatase
APOA1  Apolipoprotein A-1
APOB  Apolipoprotein B
BMI  Body mass index
BP  Blood pressure
CRM  Cardiometabolic
FM  Fat mass
GGT  Gamma-glutamyl transferase
HDL-C  High-density lipoprotein
HOMA-IR  Homeostatic model assessment index of insulin resistance
LDL-C  Low-density lipoprotein
LM  Lean mass
NAT  Neck adipose tissue
PTFQI  Parametric Thyroid Feedback Quantile-based Index
T3  Tri-iodothyronine
T4  Thyroxine
TC  Total cholesterol
TG  Triglycerides
THs  Thyroid hormones
TSH  Thyroid-stimulating hormone
VAT  Visceral adipose tissue
VO₂max  Maximum oxygen consumption
WC  Waist circumference

Key points
• Serum FT3 seems to be related to central adiposity in euthyroid adults.
• Serum FT3 seems to be linked to cardiometabolic risk factors in euthyroid adults.
• Serum TSH and FT4 are not associated with body composition or cardiometabolic risk.

Elisa Merchan-Ramirez elisamerchan@ugr.es
Jonatan R Ruiz ruizj@ugr.es

Extended author information available on the last page of the article
Introduction

The prevalence of obesity has tripled since 1975 [1]. According to the data of the World Health Organization, in 2016, 39% of the adult population was overweight and 13% was obese [1]. Obesity is characterized by excessive accumulation of body fat and an altered energy metabolism. It is considered an important public health problem worldwide due to its association with increased risk of developing cardiovascular diseases, cancer, and many other pathologies [1].

Thyroid function plays an important role in body weight and energy metabolism regulation [2]. Pathological excess of thyroid hormones (THs), reflecting a hyperthyroidism state, causes weight loss, reduces cholesterol levels, and increases resting energy expenditure, lipolysis, and glucose levels. Conversely, hypothyroidism is characterized by increased body weight and an unfavorable cardiometabolic profile [2]. Due to the important role of thyroid function in energy homeostasis [2] and cardiovascular health, several studies have investigated its relationship with obesity and cardiometabolic risk factors in euthyroid subjects [3, 4]. Both body mass index (BMI) and waist circumference (WC) are positively associated with serum-free triiodothyronine (FT3) and thyroid-stimulating hormone (TSH) levels in euthyroid subjects [5–7]. However, the relationship between obesity and free thyroxine (FT4) levels in euthyroid subjects is still controversial [5, 7]. On the other hand, previous studies have shown that moderately low (within the clinically considered normal range) FT4 and TSH levels are associated with increased glucose levels, insulin resistance, higher atherogenic lipid levels, and low-grade chronic inflammation in euthyroid subjects [8, 9]. However, the associations between insulin resistance and serum FT4 or TSH are still controversial [5, 10, 11]. Moreover, some studies have shown a positive association between serum FT3 levels and insulin resistance [5, 10, 11]. More recently, a thyroid hormone resistance index (the Parametric Thyroid Feedback Quantile based Index, PTFQI, based on the circulating concentrations of T4 and TSH) [12] has been shown to relate to the prevalence of obesity, metabolic syndrome, type 2 diabetes mellitus, and the incidence of diabetes-related deaths in the US general population, even in euthyroid subjects.

Despite the advances achieved in this field, the relationship of thyroid function with obesity and cardiometabolic risk factors in young euthyroid adults requires further investigation. BMI is the most used method to diagnose overweight and obesity. However, BMI-based diagnostic is not completely accurate due to the lack of fat mass (FM) and lean mass (LM) information. FM and LM have different physiological roles in metabolic health [13], and different FM/LM proportions at the same BMI are differentially related to insulin resistance and cardiometabolic risk factors [13]. Particularly, although the association between TH levels and body weight has been largely analyzed, the association between TH levels and body composition (i.e., FM and LM) is still unknown. Moreover, not only fat accumulation but also fat partitioning are an important risk factor for the development of cardiometabolic diseases. Visceral adipose tissue (VAT) causes insulin resistance and low-grade systemic inflammation and precedes pathological states such as metabolic syndrome and type 2 diabetes mellitus [14]. Crucially, despite that VAT mass is generally associated with total fat mass, it can largely vary between individuals with similar BMI and total fat mass [15]. Therefore, it is of great relevance to determine whether thyroid function is associated with VAT mass in euthyroid adults. Recently, other ectopic fat depots, such as neck adipose tissue (NAT) mass, have also been suggested to be a relevant indicator of cardiometabolic risk and pro-inflammatory profile [16, 17]. Since the thyroid gland function might be specially affected by this ectopic fat accumulation, to further understand the association between thyroid function and NAT mass is of clinical interest. Despite that thyroid function has been shown to be associated with classic cardiometabolic risk factors in euthyroid adults [10], whether it is also true in young euthyroid adults (18–25 years) remains to be determined. Furthermore, cardiorespiratory fitness is a better predictor of cardiovascular mortality than many classic cardiometabolic risk factors [18], and consequently, its relation with thyroid function might also bring light to the relation between the latter and cardiometabolic risk in young adults.

This study aimed to investigate the association of circulating thyroid hormones and TSH concentrations with body composition and cardiometabolic risk factors in young euthyroid adults.

Materials and methods

Participants

A total of 106 young adults (34 men, 72 women) aged 22 ± 2 years were included in this cross-sectional study (Table 1). All of them participated in the ACTIBATE study [19], an exercise-based randomized controlled trial (ClinicalTrials.gov ID: NCT02365129), from which baseline data were obtained to conduct this secondary analysis. All participants were young (18–25 years old) euthyroid adults (FT3, FT4, and TSH levels within the normal range: 2.5–4.94 pg/ml, 0.38–1.5 ng/dL, and 0.34–5.6 µU/ml, respectively) who reported: (i) being sedentary (less than 20 min on less than 3 days per week of physical activity), (ii) having a stable body weight (changes < 3 kg in the last 3 months), (iii) not being smoker, (iv) not having acute or chronic diseases, and (v) not being pregnant. The study protocol and written
Circulating concentrations of free triiodothyronine are associated with central adiposity…

Table 1 Characteristics of participants

|                      | All (n = 106) | Men (n = 34) | Women (n = 72) | P     |
|----------------------|---------------|--------------|----------------|-------|
| Age (years)          | 22.0 (2.1)    | 22.2 (2.1)   | 22.0 (2.1)     | 0.546 |
| **Thyroid hormones** |               |              |                |       |
| FT3 (pg/mL)          | 3.4 (0.4)     | 3.5 (0.3)    | 3.3 (0.4)      | 0.029 |
| FT4 (ng/dL)          | 0.9 (0.1)     | 1.0 (0.1)    | 0.9 (0.1)      | 0.077 |
| TSH (µU/mL)          | 1.7 (0.8)     | 2.0 (0.9)    | 1.6 (0.6)      | 0.004 |
| PTFQI                | 0.2 (0.3)     | 0.3 (0.2)    | 0.2 (0.2)      | 0.002 |
| **Body composition and anthropometric measurements** |               |              |                |       |
| Weight (kg)          | 70.6 (16.6)   | 83.7 (17.3)  | 64.7 (12.5)    | < 0.001 |
| Height (cm)          | 167.7 (8.9)   | 176.3 (6.9)  | 163.8 (6.7)    | < 0.001 |
| BMI (kg/m²)          | 24.9 (4.6)    | 26.9 (5.5)   | 24.0 (3.8)     | 0.002 |
| Lean mass (kg)       | 41.4 (9.8)    | 52.8 (7.4)   | 36.3 (5.4)     | < 0.001 |
| Fat mass (kg)        | 25.2 (8.8)    | 25.5 (10.9)  | 24.9 (7.7)     | 0.511 |
| Fat mass (%)         | 36.2 (7.2)    | 30.8 (7.2)   | 38.6 (5.7)     | < 0.001 |
| VAT mass (g)         | 340.6 (174.5) | 432.4 (180.9)| 299.6 (156.0)  | < 0.001 |
| WC (cm)              | 80.9 (13.8)   | 89.8 (15.1)  | 76.8 (11.1)    | < 0.001 |
| **Cardiometabolic risk factors** |               |              |                |       |
| Glucose (mg/dL)      | 87.5 (6.7)    | 89.6 (7.7)   | 86.5 (6.0)     | 0.027 |
| Insulin (µUI/mL)     | 8.5 (5.0)     | 9.5 (6.7)    | 8.1 (4.0)      | 0.196 |
| HOMA-IR              | 1.9 (1.3)     | 2.2 (1.7)    | 1.8 (1.0)      | 0.124 |
| Total-cholesterol (mg/dL) | 164.5 (29.4) | 163.4 (32.4) | 164.9 (28.2)  | 0.806 |
| HDL-C (mg/dL)        | 52.3 (11.0)   | 45.3 (7.9)   | 55.5 (10.8)    | < 0.001 |
| LDL-C (mg/dL)        | 96.2 (24.6)   | 99.8 (27.1)  | 94.5 (23.4)    | 0.302 |
| Triglycerides (mg/dL)| 83.2 (47.5)   | 91.4 (48.3)  | 79.5 (47.0)    | 0.228 |
| LDL-C/HDL-C ratio    | 1.9 (0.7)     | 2.3 (0.8)    | 1.8 (0.5)      | < 0.001 |
| TG/HDL-C ratio       | 1.7 (1.3)     | 2.2 (1.6)    | 1.5 (1.0)      | 0.003 |
| TC/HDL-C ratio       | 3.2 (0.9)     | 3.7 (1.1)    | 3.0 (0.6)      | < 0.001 |
| APOA1 (mg/dL)        | 144.5 (27.8)  | 128.2 (18.1) | 151.8 (28.4)   | < 0.001 |
| APOB (mg/dL)         | 70.4 (20.3)   | 73.9 (25.1)  | 68.8 (17.8)    | 0.239 |
| C-reactive-protein (mg/L) | 2.5 (3.3) | 2.1 (2.3) | 2.7 (3.6) | 0.406 |
| Homocysteine (µmol/L)| 10.9 (3.4)    | 12.8 (3.9)   | 10.0 (2.7)     | < 0.001 |
| Leptin (µg/L)        | 6.2 (4.0)     | 4.7 (4.0)    | 6.9 (3.9)      | 0.006 |
| Adiponectin (mg/L)   | 11.1 (8.0)    | 7.6 (5.7)    | 12.7 (8.4)     | 0.002 |
| GGT (U/L)            | 18.8 (18.9)   | 28.9 (30.8)  | 14.1 (4.7)     | < 0.001 |
| ALP (U/L)            | 72.5 (18.9)   | 79.7 (19.5)  | 69.2 (17.9)    | 0.007 |
| CMR score            | 0.0 (0.7)     | -0.0 (0.7)   | 0.0 (0.6)      | 0.839 |
| Fatty liver index    | 20.5 (24.7)   | 36.8 (31.7)  | 12.8 (15.5)    | < 0.001 |
| Systolic BP (mmHg)   | 116.2 (11.7)  | 124.7 (11.3) | 112.4 (9.7)    | < 0.001 |
| Diastolic BP (mmHg)  | 71.0 (7.5)    | 72.8 (8.8)   | 70.1 (6.8)     | 0.094 |
| Mean BP (mmHg)       | 85.9 (8.0)    | 89.9 (8.6)   | 84.1 (7.1)     | < 0.001 |
| VO₂ max (mL/kg/min)  | 40.9 (8.1)    | 44.8 (8.8)   | 39.1 (7.1)     | 0.001 |

Data are presented as mean and standard deviation. P value is from an independent samples t-test comparing men vs women. Abbreviations: FT3, free triiodothyronine; FT4, free Thyroxine; TSH, Thyroid-Stimulating Hormone; PTFQI, Parametric Thyroid Feedback Quantile based Index; BMI, body mass index; LMI, lean mass index, FMI, fat mass index; VAT, visceral adipose tissue; NAT, neck adipose tissue; HOMA-IR, homeostatic model assessment-insulin resistance; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglycerides; TC, total cholesterol; APOA1, apolipoprotein A-1; APOB, apolipoprotein B; GGT, gamma-glutamyltransferase; ALP, Alkaline phosphatase; CRM score, cardiometabolic risk score; BP, blood pressure; VO₂ max, maximum oxygen consumption; WC, waist circumference
informed consent were performed in accordance with the Declaration of Helsinki. The Ethics Committee of Human Research of the University of Granada (no 924) and the Servicio Andaluz de Salud (Centro de Granada, CEI-Granada, no 20.10.2014) approved the study. For logistic reasons, the measurements were conducted in eight evaluation waves, which means that participants were measured in different groups during the months of October, November, and December in 2015 and 2016.

**Thyroid function**

A blood draw was taken after a 6-h fast and after avoiding moderate (within 24 h) and vigorous (within 48 h) physical activity in the previous days. The blood draw took place between 8 am and 6:30 pm (no association was found between the time of the day when the samples were collected and the concentrations of FT3, FT4, and TSH, data not shown). Upon collection, blood was centrifuged and stored at 4 °C until analyses. FT3, FT4, and TSH circulating levels were determined using a Beckman Coulter DXI (33,880) chemiluminescent immunoassay system (Intra-assay CV FT3 = 5.7%, FT4 = 4.95%, TSH = 5.86%). In addition, we calculated the PTFQI — an indicator of resistance to thyroid hormones — which oscillates between − 1 and 1 [12]. Hence, negative values of this index indicate low TSH values by high inhibition of FT4, which indicates high sensitivity to FT4. In contrast, positive PTFQI values indicate high TSH values by high inhibition of FT4, which indicates high sensitivity to FT4. Therefore, PTFQI evaluate the set point of the central regulation of THs concentration. PTFQI was calculated following Excel spreadsheet formula created by Laclaustra et al. [12].

**Body composition and anthropometric measurements**

A whole-body dual-energy X-ray absorptiometry scan (Discovery Wi, Hologic, Inc., Bedford, MA, USA) was used to determine FM, LM, and VAT mass. Data were obtained from the Hologic APEX 4.0.2. (Hologic, Inc., Bedford, MA, USA) software. Weight and height of participants were measured without shoes and wearing light clothes using a SECA scale and stadiometer (model 799, Electronic Column Scale, Hamburg, Germany), and body mass index was calculated (kg/m²). Waist circumference (cm) was measured twice at the minimum perimeter, or at the medium point between the inferior rib and the iliac crest when the minimum perimeter was not apparent, with an inextensible metallic tape, in the standing position, and the average value was considered for further analyses.

NAT volume was determined by the analyses of the computerized tomography (CT) being part of a Positron Emission Tomography/Computerized tomography [Siemens 16 PET/CT scanner (Siemens, Erlangen, Germany)] that was carried out in the ACTIBATE study for quantifying brown adipose tissue volume [19]. The CT scans were performed from the atlas vertebra to the mid-chest region, and all of them were analyzed using the FIJI software ([http://sourceforge.net/projects/fijiplugins/](http://sourceforge.net/projects/fijiplugins/)) [20]. NAT volume was determined at the level of C5, as previously described [17]. We obtained the total NAT volume applying a radiodensity range of –300 to –10 Hounsfield units. NAT volume was then multiplied by a fat density coefficient of 0.9 g/ml to obtain the total NAT mass [21].

**Circulating cardiometabolic risk markers**

Blood samples for determining cardiometabolic risk factors were obtained in the morning after an overnight fast (> 10 h), in resting conditions. Blood was later centrifuged, and serum aliquots were stored at −80 °C until analyses. Fasting blood glucose concentration was determined by Beckman Coulter reagent OSR6521 in a Beckman Coulter AU5832 analyzer. Insulin concentration was determined by Chemiluminescent immunoassay of Beckman Coulter (33,410) with a DXI analyzer. The homeostatic model assessment index of insulin resistance (HOMA-IR) was calculated [22]. Concentrations of total cholesterol, triglyceride, Apolipoprotein A (APO A), and high-density lipoprotein cholesterol (HDL-C) were obtained with routine enzymatic methods with a Beckman Coulter AU5832 analyzer. To determine low-density lipoprotein cholesterol (LDL-C) concentration, the Friedewald formula was used [23]. Lipoprotein ratios (LDL-C/HDL-C, TG/HDL-C, and TC/HDL-C) were calculated as markers of dyslipidemia [24].

To measure the concentrations of C-reactive protein (CRP), Beckman Coulter reagent OSR6299 was used with an immunoturbidimetric method and then samples were processed in a Beckman Coulter AU5833 analyzer. Reagent from Axis-Shield Diagnostics Ltd (B08176) was used in a colorimetric method to determine homocysteine concentration in the Beckman Coulter AU5833 analyzer. The Beckman Coulter 447,730 reagent was used with an immunoturbidimetric method to determine the Apolipoprotein B (APO B) levels in the Beckman Coulter AU5833 analyzer. To measure gamma-glutamyl transferase (GGT) and Alkaline phosphatase (ALP) concentrations, Beckman Coulter reagent was used with a colorimetric method of the International Federation of Clinical Biochemistry (IFCC) in a Beckman Coulter AU5832 analyzer. Adiponectin concentration was determined with the MILLIPLEX MAP Human Adipokine Magnetic Bead Panel 2 (Catalogue # HADK2MAG-61 K; Intra-assay CV = 9%) and leptin concentration was determined with the MILLIPLEX MAP Human Adipokine Magnetic Bead Panel 1 (Catalogue # HADK1MAG-61 K;...
Intra-assay CV = 9%), both using Luminex MAP Technology platform (Luminex Corporation, Austin, TX, USA).

**Blood pressure**

Blood pressure was assessed with an automatic sphygmomanometer Omron M2 (Omron Healthcare, Kyoto, Japan) on three different days, while the participant rested seated. The average of systolic and diastolic pressure on the three different days was calculated. Later, mean blood pressure (MBP) was calculated as follows [25]:

\[
MBP = \text{Diastolic blood pressure} + 0.33 \\
\times (\text{Systolic blood pressure} - \text{Diastolic blood pressure})
\]

**Combined cardiometabolic risk factors**

**Clustered score for cardiometabolic risk factors**

A clustered score for cardiometabolic risk factors, based on diagnostic criteria of metabolic syndrome, was calculated [26]. Firstly, sex-specific Z-scores were obtained for waist circumference, mean blood pressure, HDL-C, triglycerides, and glucose. The cardiometabolic risk factors score was the average of the inverse Z-score of HDL-C and Z-scores of triglycerides, glucose, waist circumference, and mean blood pressure.

**Fatty liver index**

The fatty liver index (FLI) was calculated with the following formula proposed by Bedogni et al. [27]:

\[
FLI = \frac{e^{2.953 - \log(\text{triglycerides}) + 0.139 \times \text{BMI} - 0.738 + \log(\text{GGT}) - 0.053 \times \text{waist circumference} - 15.745}}{(1 + e^{2.953 - \log(\text{triglycerides}) + 0.139 \times \text{BMI} - 0.738 + \log(\text{GGT}) - 0.053 \times \text{waist circumference} - 15.745)} 100
\]

**Cardiorespiratory fitness assessment**

Maximum oxygen consumption (VO2max) was determined by an incremental maximal graded treadmill (H/P/Cosmos Sport & Medical GMBH, Germany) walking test applying the modified Balke protocol [19, 28]. Participants did not consume stimulants 24 h before the test, fasted 3 to 5 h and did not perform vigorous or moderate physical activity (48 h and 24 h, respectively) before the test [19, 29]. The gas exchange was continuously registered by indirect calorimetry (Ultima CardiO2 cart, Medgraphics Corp, Minnesota, USA) with an oronasal mask (model 7400, Hans Rudolph Inc, Kansas City, MO, USA). VO2 was averaged every 5 s employing the Breeze Suite software (version 8.1.0.54 SP7, MGC Diagnostic®) and the highest observed VO2 after removing apparent artifacts were defined as the VO2max.

Heart rate was continuously measured during the test with a heart rate monitor (Polar RS800X, Polar Electro Öy, Kempele, Finland).

**Statistical analyses**

Data are reported as mean and standard deviation. To study the association of FT3, FT4, and TSH, and serum levels and PTFQI, with body composition parameters and cardiometabolic risk factors, we conducted simple linear regressions. All variables were transformed (square root transformation), except PTFQI, to normalize its distribution. Moreover, we also tested these associations using multiple linear regressions adjusting for sex. The sex × TSH/THs interaction effect on body composition/cardiometabolic risk factors was also analyzed for all the associations. Error alpha propagation by multiple comparisons correction (Benjamini–Hochberg procedure [30]) was performed. The Statistical Package for Social Sciences (SPSS, v. 22.0, IBM SPSS Statistics, IBM Corporation) was used to perform the analyses. The GraphPad Prism 8 (GraphPad Software, San Diego, CA, USA) was used to build the graphical plots. Statistical significance was set at P < 0.05.

**Results**

FT3 was positively associated with BMI (β = 0.201; \(R^2 = 0.041; P = 0.038\)), LM (β = 0.244; \(R^2 = 0.059; P = 0.014\)), VAT mass (β = 0.240; \(R^2 = 0.058; P = 0.016\)), and WC (β = 0.221; \(R^2 = 0.049; P = 0.025\)) (Fig. 1). Despite that there were no sex interaction effects, the associations between FT3 and VAT were attenuated after adjusting for sex (β = 0.174; \(R^2 = 0.150; P = 0.072\)), and the association with BMI, WC, or LM disappeared (all \(P > 0.13\)) (data not shown). In contrast, FT4 was not associated with any body composition parameter (all \(P > 0.080\)) (Fig. 2). TSH was positively associated with LM (β = 0.268; \(R^2 = 0.072; P = 0.007\)) (Fig. 3), but the association disappeared after adjusting for sex (β = 0.072; \(R^2 = 0.619; P = 0.673\), data not shown). PTFQI was also positively associated with LM (β = 0.243; \(R^2 = 0.059; P = 0.015\)) and VAT mass (β = 0.210; \(R^2 = 0.044; P = 0.036\) (Figure S2), but these associations disappeared after having been adjusted for sex (\(P > 0.271\), data not shown). No associations were found between FT3, FT4, TSH, or PTFQI and total NAT mass (Figure S3). The association analyses in men and women separately can be found in Table S1.

Figure S1 and Table 2 show the associations of THs and TSH with cardiometabolic risk factors. FT3 was positively associated with glucose, insulin, HOMA-IR, GGT, fatty liver index, systolic blood pressure, diastolic blood pressure, and mean blood pressure (all \(P < 0.024\), Table 2). However,
the associations between FT3 and cardiometabolic risk factors disappeared after adjusting for VAT mass (data not shown), except for the association between FT3 and systolic and mean blood pressure ($\beta = 0.170$; $R^2 = 0.373$; $P = 0.038$ and $\beta = 0.171$; $R^2 = 0.347$; $P = 0.041$, respectively). FT4 was negatively associated with adiponectin, and positively associated with systolic blood pressure, diastolic blood pressure, and mean blood pressure (all $P < 0.047$), but not with the rest of cardiometabolic risk factors (all $P > 0.075$; Table 2). A negative association was observed between TSH and HDL-C, and positive associations were found between TSH and LDL-C/HDL-C ratio, TG/HDL-C ratio, TC/HDL-C ratio, homocysteine, and SBP (all $P < 0.039$, Table 2), but no other association was observed between TSH and other cardiometabolic risk factors (all $P > 0.051$, Table 2). Cardiorespiratory fitness was not associated with any thyroid metabolism variables ($P \geq 0.662$, data not shown). All the associations between FT4, TSH, and cardiometabolic risk factors remained after adjusting for VAT mass (data not shown). PTFQI was negatively associated with adiponectin, and was positively associated with homocysteine, systolic blood pressure, diastolic blood pressure, and mean blood pressure (all $P < 0.023$, Table 2). All the associations between THs and cardiometabolic risk factors were attenuated when adjusting for sex (Table S2).

The relationship of thyroid function with resting and peak heart rate was also explored and no associations were found (data not shown).
Circulating concentrations of free triiodothyronine are associated with central adiposity…

A significant sex × FT3 interaction effect was found on homocysteine (P = 0.002) levels. The sex × FT4 interaction was significant on leptin levels (P = 0.036). A significant sex × TSH interaction effect was also observed on total cholesterol (P = 0.017) and APOB (P = 0.014) levels. The association analyses in men and women separately can be found in Table S2.

None of the associations previously reported between thyroid function and body composition and cardiometabolic risk factors remained after alpha error propagation correction (data not shown).

Discussion

The results of this study show that FT3 is positively associated with BMI, lean mass, central adiposity, and several cardiometabolic risks factors in young euthyroid adults. However, these associations were attenuated when adjusting for sex, and only some of them remained when analyzing men and women separately, which might point to a relevant role of sex in this relationship. On the other hand, we found no associations between FT4, TSH, and PTFQI and body composition parameters or cardiometabolic risk factors. These findings suggest that thyroid function, even when circulating levels of THs and TSH...
are within the normal range, might be related to body composition and cardiovascular risk in euthyroid young adults.

Several studies have analyzed the relationship between FT3 and adiposity [7, 11], but few have evaluated the connection between thyroid function and central adiposity in euthyroid young adults. Central adiposity is an important risk factor in the development of metabolic syndrome and cardiovascular disease [31]. We observed a positive association of FT3 with WC and VAT mass in young euthyroid adults. These results are in agreement with previous studies in euthyroid older obese subjects [8, 11]. Despite that VAT is commonly associated with ectopic fat deposition, we found no association of FT3, FT4, or TSH concentrations with total NAT mass. Moreover, we found no association of any body composition variable with FT4 or TSH, in agreement with the results obtained by Manji et al. [32]. Future studies should evaluate the relationship between thyroid function and central adiposity to understand the potential causes underlying the positive associations observed in studies [7].

Metabolic syndrome includes several risk factors for cardiovascular disease, namely, central obesity, elevated blood pressure, atherogenic dyslipidemia (high triglycerides and low HDL-C), and hyperglycemia. We observed the cardiometabolic risk score being positively associated with FT3 in euthyroid young adults. The relationship between thyroid function, insulin resistance, and
Circulating concentrations of free triiodothyronine are associated with central adiposity…

Table 2 Association between serum levels of thyroid-stimulating hormone (TSH), thyroid hormones and Parametric Thyroid Feedback Quantile based Index (PTFQI) with cardiometabolic risk factors

| FT3 (pg/mL) | FT4 (ng/dL) | TSH (µUI/mL) | PTFQI |
|-------------|-------------|---------------|-------|
| β | R² | P | β | R² | P | β | R² | P | β | R² | P |
| Glucose | 0.224 | 0.050 | 0.022 | 0.075 | 0.006 | 0.450 | 0.095 | 0.009 | 0.340 | 0.106 | 0.011 | 0.283 |
| Insulin | 0.263 | 0.069 | 0.007 | 0.141 | 0.020 | 0.153 | 0.082 | 0.007 | 0.409 | 0.120 | 0.014 | 0.225 |
| HOMA-IR | 0.269 | 0.072 | 0.006 | 0.134 | 0.018 | 0.174 | 0.089 | 0.008 | 0.371 | 0.122 | 0.015 | 0.218 |
| Total cholesterol | -0.117 | 0.014 | 0.237 | -0.019 | <0.001 | 0.848 | 0.060 | 0.004 | 0.543* | 0.050 | 0.002 | 0.617 |
| LDL-C | -0.073 | 0.005 | 0.461 | -0.031 | 0.001 | 0.754 | 0.095 | 0.009 | 0.336 | 0.061 | 0.004 | 0.540 |
| HDL-C | -0.192 | 0.037 | 0.051 | -0.038 | 0.001 | 0.704 | -0.225 | 0.051 | 0.021 | -0.175 | 0.031 | 0.075 |
| Triglycerides | 0.306 | 0.094 | 0.001 | 0.194 | 0.038 | 0.147 | 0.172 | 0.008 | 0.371 | 0.122 | 0.015 | 0.218 |
| LDL-C/HDL-C ratio | 0.072 | 0.005 | 0.468 | 0.004 | <0.001 | 0.970 | 0.206 | 0.043 | 0.035 | 0.152 | 0.023 | 0.124 |
| TG/HDL-C ratio | 0.077 | 0.013 | 0.185 | 0.006 | <0.001 | 0.951 | 0.236 | 0.056 | 0.016 | 0.145 | 0.021 | 0.141 |
| TC/HDL-C ratio | 0.095 | 0.009 | 0.336 | 0.026 | 0.001 | 0.793 | 0.239 | 0.057 | 0.015 | 0.191 | 0.036 | 0.052 |
| CMR Score | 0.012 | 0.021 | 0.211 | -0.040 | 0.002 | 0.690 | -0.193 | 0.037 | 0.051 | -0.158 | 0.025 | 0.111 |
| APOA1 | -0.124 | 0.001 | 0.009 | -0.063 | 0.034 | 0.486* | 0.063 | 0.004 | 0.528 |
| APOB | <0.001 | 0.109 | 0.012 | 0.270 | 0.121 | 0.015 | 0.219 | -0.092 | 0.008 | 0.352 | -0.018 | <0.001 | 0.854 |
| HOMA-IR | 0.015 | 0.023 | 0.123* | 0.024 | 0.001 | 0.810 | 0.250 | 0.062 | 0.011 | 0.222 | 0.049 | 0.023 |
| C reactive protein | -0.008 | <0.001 | 0.037 | -0.175 | 0.031 | 0.075* | -0.118 | 0.014 | 0.233 | -0.189 | 0.036 | 0.054 |
| Homocysteine | -0.129 | 0.017 | 0.193 | -0.218 | 0.047 | 0.027 | -0.168 | 0.028 | 0.089 | -0.260 | 0.068 | 0.008 |
| Adiponectin | 0.263 | 0.069 | 0.007 | 0.072 | 0.005 | 0.472 | -0.025 | 0.001 | 0.805 | 0.044 | 0.002 | 0.657 |
| GGT | 0.149 | 0.022 | 0.007 | 0.072 | 0.004 | 0.608 | -0.001 | <0.001 | 0.864 | 0.007 | <0.001 | 0.947 |
| ALP | 0.188 | 0.035 | 0.054 | 0.029 | 0.001 | 0.766 | 0.081 | 0.007 | 0.407 | 0.062 | 0.004 | 0.527 |
| CMR Score | 0.260 | 0.067 | 0.009 | 0.051 | 0.003 | 0.615 | 0.126 | 0.016 | 0.210 | 0.115 | 0.013 | 0.252 |
| Fatty liver index | 0.306 | 0.094 | 0.001 | 0.194 | 0.038 | 0.047 | 0.202 | 0.041 | 0.039 | 0.283 | 0.080 | 0.003 |
| Systolic BP | 0.246 | 0.061 | 0.011 | 0.238 | 0.057 | 0.014 | 0.061 | 0.004 | 0.534 | 0.237 | 0.056 | 0.015 |
| Diastolic BP | 0.301 | 0.091 | 0.002 | 0.243 | 0.059 | 0.012 | 0.136 | 0.018 | 0.168 | 0.285 | 0.081 | 0.003 |
| Mean BP | 0.008 | <0.001 | 0.007 | 0.030 | 0.001 | 0.766 | 0.009 | 0.019 | <0.001 | 0.848 |
| VO₂max | 0.259 | 0.072 | 0.006 | 0.060 | 0.004 | 0.543 | 0.050 | 0.002 | 0.617 |

Standardized β coefficient, R², and P value from simple linear regression analyses. *Significant sex interaction. All variables were transformed (square root transformation), except PTFQI. Abbreviations: FT3, free triiodothyronine; FT4, free thyroxine; TSH, thyroid-stimulating hormone; HOMA-IR, homeostatic model assessment index of insulin resistance; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglycerides; APOA1, apolipoprotein A-1; APOB, apolipoprotein B; GGT, gamma-glutamyltransferase; ALP, Alkaline phosphatase; CRP, C reactive protein; CMR Score, cardiometabolic risk score; FLI, fatty liver index; BP, blood pressure; VO₂max, maximum oxygen consumption.

The relationship between THs and blood pressure has also been extensively studied in pathological states, although this relationship still remains unclear in euthyroid subjects. In our study, THs and PTFQI were positively associated with systolic, diastolic, and mean blood pressure, and these results persist after adjusting for sex. However, no association was found between TSH and blood pressure, which concur with the finding by Roos et al. [37]. THs are important for vascular function. Both T3 and T4 act as a vasodilator on vascular smooth muscle cells [38]. Therefore, an increase of THs concentration in euthyroid subjects might represent a compensation for high blood pressure values. Alternatively, elevated concentrations of THs might itself contribute to increased blood pressure. Hyperthyroidism can produce tachycardia, increased heart contractility, elevated cardiac output, high systolic pressure, increased pulse pressure, and muscle weakness [39]. Therefore, elevated THs within the normal range could have the same effect as those in the hyperthyroid state, increasing blood pressure.
THs are important regulators of various metabolic processes, such as lipid metabolism [40]. The association between THs concentrations and serum lipids in pathological states has for long been studied [41, 42]. However, this relationship in euthyroid subjects is not clear yet. We observed a tendency to the negative association of FT3, TSH, and PTFQI with HDL-C, which is in agreement with Bakker et al. [43]. Hypothyroidism had been reported to be associated with an increased risk for dyslipidemia (especially higher serum levels of cholesterol, whereas their levels are reduced in hyperthyroidism) and atherosclerotic cardiovascular disease [44]. This phenomenon appears to be related to the cholesterol ester transfer protein (CETP) activity. CETP is positively regulated by THs, regulating the exchange of cholesteryl-ester between HDL-C and very-low-density lipoprotein (VLDL). Higher activity of CETP would imply an increased cardiovascular risk, related to elevation of VLDL and decreased HDL-C serum levels [40]. Thus, it is plausible that the tendency to an inverse association that we found of FT3, TSH, and PTFQI with HDL-C, is mediated by this mechanism, even in euthyroid subjects.

Cardiorespiratory fitness is currently recognized as an important marker of cardiovascular health, as it integrates the function of many physiological systems [18]. Therefore, we also investigated whether thyroid hormones are associated with cardiorespiratory fitness. Despite that FT3 was associated with many cardiometabolic risk factors, no association was found between TSH/THs and cardiorespiratory fitness in euthyroid adults.

Limitations

The present results need to be interpreted with caution, since some limitations are present. First, it is a cross-sectional study and, therefore, no causality can be established. In addition, only healthy young adults are included in the study, so the results are not extrapolatable to older, younger, or unhealthy people. Furthermore, blood samples were measured at different times of the day, and due to the known circadian variations of THs levels, the results should be taken with caution. Moreover, despite that roughly two-thirds of the study sample were women, we did not standardize and neither controlled the menstrual cycle, which might have contributed to bias the results. Finally, despite that DXA is a valid instrument to assess body composition, it is limited to accurately assess VAT mass. Other more precise techniques such as magnetic resonance might have been more informative concerning the relationship between thyroid function and body composition. Likewise, other techniques such as lipoprotein profile analyses or hyperinsulinemic clamps for determining insulin resistance might be able to better detect relationships between thyroid function and cardiometabolic risk.

Conclusion

In summary, FT3 seems to be associated with central adiposity and metabolic syndrome factors such as insulin resistance, mean, systolic and diastolic blood pressure, and fatty liver in euthyroid young adults. More studies are needed in this population to clarify the role of thyroid function in the development and prevention of cardiovascular diseases at early ages.

Supplementary information The online version contains supplementary material available at https://doi.org/10.1007/s13105-022-00881-w.

Acknowledgements This work is part of a PhD thesis conducted within the framework of the Biomedicine Doctoral Studies Program of the University of Granada, Spain.

Author contribution Conceptualization, validation, formal analysis, data curation, and visualization: EMR, GSD. Methodology and writing—original draft: EMR, GSD, JRR. Investigation: EMR, GSD, FMA, MJAT, CAA, MMT, JMLLE, JRR. Resources: JMLLE, JRR. Writing—Review & Editing: EMR, GSD, FMA, CAA, MJAT, MMT, JMLLE, JRR. Supervision and Project administration: GSD, JRR. Funding acquisition: JRR. The authors declare that all data were generated in-house and that no paper mill was used.

Funding Funding for open access charge: Universidad de Granada / CBUA. This study was funded by the Spanish Ministry of Economy and Competitiveness via the Fondo de Investigación Sanitaria del Instituto de Salud Carlos III (PI13/01393), by the Retos de la Sociedad program (DEP2016-79512-R), European Regional Development Funds (ERDF), the Spanish Ministry of Education (FPU13/04365), the Fundación Iberoamericana de Nutrición (FINUT), the Redes Temáticas de Investigación Cooperativa RETIC (Red SAMID RD16/0022), the AstraZeneca HealthCare Foundation, the University of Granada Plan Propio de Investigación 2016—Excellence actions: Unit of Excellence on Exercise and Health (UCEES)—and Plan Propio de Investigación 2018—the Programa Contratos-Puente and Contratos Perfeccionamiento de Doctores, the Junta de Andalucía, Consejería de Conocimiento, Investigación y Universidades (ERDF; ref. SOMM17/6107/UGR), and the Fundación Alfonso Martín Escudero (grant awarded to GSD).

Data availability The datasets generated and/or analyzed during this study are available upon reasonable request.

Declarations

Conflict of interest The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Circulating concentrations of free triiodothyronine are associated with central adiposity...

References

1. WHO (2020) Obesity and overweight. In: World Heal. Organ. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight

2. Mullur R, Liu Y, Brent GA (2014) Thyroid hormone regulation of metabolism. Physiol Rev 94:355–382. https://doi.org/10.1152/physrev.00030.2013

3. Kivimäki M, Kuosma E, Ferrie JE et al (2017) Overweight, obesity, and risk of cardiometabolic multimorbidity: pooled analysis of individual-level data for 120 813 adults from 16 cohort studies from the USA and Europe. Lancet Public Heal 2:e277–e285. https://doi.org/10.1016/S2468-2667(17)30074-9

4. Liu J, Duan Y, Fu J, Wang G (2018) Association between thyroid hormones, thyroid antibodies, and cardiometabolic factors in non-obese individuals with normal thyroid function. Front Endocrinol (Lausanne) 9:1–6. https://doi.org/10.3389/fendo.2018.00130

5. Kwon H, Cho JH, Lee DY et al (2018) Association between thyroid hormone levels, body composition and insulin resistance in euthyroid subjects with normal thyroid ultrasound: The Kang-buk Samsung Health Study. Clin Endocrinol (Oxf) 89:649–655. https://doi.org/10.1111/cen.13823

6. De Pergola G, Ciampolillo A, Paolotti S et al (2007) Free triiodothyronine and thyroid stimulating hormone are directly associated with waist circumference, independently of insulin resistance, metabolic parameters and blood pressure in overweight and obese women. Clin Endocrinol (Oxf) 67:265–269. https://doi.org/10.1111/j.1365-2265.2007.02874.x

7. Kitahara CM, Platz EA, Ladenson PW et al (2012) Body fatness and markers of thyroid function among U.S. men and women. PLoS One 7:1–6. https://doi.org/10.1371/journal.pone.0034979

8. Laclaustra M, Hurtado-Roca Y, Sendin M et al (2015) Lower-normal TSH is associated with better metabolic risk factors: a cross-sectional study on Spanish men. Nutr Metab Cardiovasc Dis 25:1095–1103. https://doi.org/10.1016/j.numecd.2015.09.007

9. Singh S, Duggal J, Molnar J, et al (2008) Impact of subclinical thyroid disorders on coronary heart disease, cardiovascular and all-cause mortality: a meta-analysis. Int J Cardiol 125(1):41–48. https://doi.org/10.1016/j.ijcard.2007.02.027

10. Roef G, Lapauw B, Goemaere S et al (2012) Body composition and metabolic parameters are associated with variation in thyroid hormone levels among euthyroid young men. Eur J Endocrinol 167:719–726. https://doi.org/10.1530/EJE-12-0447

11. Ren R, Jiang X, Zhang X et al (2014) Association between thyroid hormones and body fat in euthyroid subjects. Clin Endocrinol (Oxf) 80:585–590. https://doi.org/10.1111/cen.12131

12. Laclaustra M, Moreno-Franco B, Lou-Bonafonte JM et al (2019) Impaired sensitivity to thyroid hormones is associated with diabetes and metabolic syndrome. Diabetes Care 42:303–310. https://doi.org/10.2337/dc18-1410

13. Hirsch KR, Smith-Ryan AE, Blue MNN et al (2016) Metabolic characterization of overweight and obese adults. Phys Sportsmed 44:362–372. https://doi.org/10.1080/00913847.2016.1248222

14. Jayedi A, Soltani S, Zargar MS, et al (2020) Central fatness and risk of all cause mortality: systematic review and dose-response meta-analysis of 72 prospective cohort studies. BMJ 370https://doi.org/10.1136/bmj.m3374

15. Neeland IJ, Ross R, Després JP et al (2019) Visceral and ectopic fat accumulation and its relation to cardiovascular risk and metabolic syndrome. Am J Clin Nutr 100:1244–1251. https://doi.org/10.3945/ajcn.114.086450

16. Torrini M, Gill CM, Daley S et al (2014) Compartmental neck fat accumulation and its relation to cardiovascular risk and metabolic syndrome. Am J Clin Nutr 100:1244–1251. https://doi.org/10.3945/ajcn.114.086450

17. Arias-Tellez MJ, Acosta FM, Garcia-Rivero Y et al (2020) Neck adipose tissue accumulation is associated with higher overall and central adiposity, a higher cardiometabolic risk, and a pro-inflammatory profile in young adults. Int J Obes (Lond). https://doi.org/10.1038/s41366-020-00701-5

18. Artero EG, España-Romero V, Lee D et al (2012) Ideal cardiovascular health and mortality: Aerobics Center Longitudinal Study. Mayo Clin Proc 87:944–952. https://doi.org/10.1016/j.mayocp.2012.07.015

19. Sanchez-Delgado G, Martinez-Tellez B, Olza J et al (2015) Activating brown adipose tissue through exercise (ACTIBATE) in young adults: rationale, design and methodology. Contemp Clin Trials 45:416–425. https://doi.org/10.1016/j.cct.2015.11.004

20. Schindelin J, Arganda-Carreras I, Frise E et al (2012) Fiji: an open-source platform for biological-image analysis. Nat Methods 9:676–682. https://doi.org/10.1038/nmeth.2019

21. Siri WE (1993) Body composition from fluid spaces and density: analysis of methods. 1961. Nutrition 9:480–91 (discussion 480, 492)

22. Bonora E, Targher G, Alberiche M et al (2000) Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 23:57–63. https://doi.org/10.2337/diacare.23.1.57

23. Kannan S, Mahadevan S, Ramji B et al (2014) LDL-cholesterol: Friedewald calculated versus direct measurement-study from a large Indian laboratory database. Indian J Endocrinol Metab 18:502–504. https://doi.org/10.4103/2230-8210.137496

24. Millán J, Pintó X, Muñoz A et al (2009) Lipoprotein ratios: physiological significance and clinical usefulness in cardiovascular prevention. Vasc Health Risk Manag 5:757–765

25. Amouzegar A, Heidari M, Gharibzadeh S et al (2016) The association between blood pressure and normal range thyroid function tests in a population based Tehran thyroid study. Horm Metab Res 48:151–156. https://doi.org/10.1555/s-0035-1564131

26. Min K-B, Min J-Y, Paek D, Cho S-I (2008) The impact of the components of metabolic syndrome on heart rate variability: using the NCEP-ATP III and IDF definitions. Pacing Clin Electrophysiol 31:584–591. https://doi.org/10.1111/j.1540-8159.2008.01045.x

27. Bedogni G, Bellentani S, Miglioli L et al (2006) The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 6:1–7. https://doi.org/10.1186/1471-230X-6-33

28. Balke B, Ware RW (1959) An experimental study of physical fitness of Air Force personnel. U S Armed Forces Med J 10:675–688

29. Amaro-Gahete FJ, De-La-O A, Jurado-Fasoli L et al (2019) Changes in physical fitness after 12 weeks of structured concurrent exercise training, high intensity interval training, or whole-body electromystimulation training in sedentary middle-aged adults: a randomized controlled trial. Front Physiol 10:1–15. https://doi.org/10.3389/fphys.2019.00451

30. Benjamini Y, Drai D, Elmer G et al (2001) Controlling the false discovery rate in behavior genetics research. Behav Brain Res 125:279–284. https://doi.org/10.1016/s0166-4328(01)00297-2

31. Zhang P, Wang R, Gao C et al (2016) Prevalence of central obesity among adults with normal BMI and its association with metabolic diseases in Northeast China. PLoS One 11:e0160402–e0160402. https://doi.org/10.1371/journal.pone.0160402

32. Manji N, Boelaert K, Sheppard MC et al (2006) Lack of association between serum TSH or free T4 and body mass index in euthyroid subjects. Clin Endocrinol (Oxf) 64:125–128. https://doi.org/10.1111/j.1365-2265.2006.02433.x

33. De Pergola G, Giorgino F, Benigno R et al (2008) Independent influence of insulin, catecholamines, and thyroid hormones on metabolic syndrome. Obesity (Silver Spring) 16:2405–2411. https://doi.org/10.1038/oby.2008.382
34. Andersen OO, Friis T, Ottesen B (1977) Glucose tolerance and insulin secretion in hyperthyroidism. Acta Endocrinol (Copenh) 84:576–587. https://doi.org/10.1530/acta.0.0840576
35. Dimitriadis G, Mitrou P, Lambadiari V et al (2006) Insulin action in adipose tissue and muscle in hypothryroidism. J Clin Endocrinol Metab 91:4930–4937. https://doi.org/10.1210/jc.2006-0478
36. Ferrannini E, Iervasi G, Cobb J et al (2017) Insulin resistance and normal thyroid hormone levels: prospective study and metabolomic analysis. Am J Physiol - Endocrinol Metab 312:E429–E436. https://doi.org/10.1152/ajpendo.00464.2016
37. Roos A, Bakker SJL, Links TP et al (2015) Thyroid function is associated with components of the metabolic syndrome in euthyroid subjects. J Clin Endocrinol Metab 92:491–496. https://doi.org/10.1210/jc.2010-2373
38. Ojamaa K, Klemperer JD, Klein I (1996) Acute effects of thyroid hormone on vascular smooth muscle. Thyroid 6:505–512. https://doi.org/10.1089/thy.1996.6.505
39. Danzi S, Klein I (2003) Thyroid hormone and blood pressure regulation. Curr Hypertens Rep 5:513–520. https://doi.org/10.1007/s11906-003-0060-7
40. Duntas LH (2002) Thyroid disease and lipids. Thyroid 12:287–293. https://doi.org/10.1089/10507250225949405
41. O’Brien T, Dinneen SF, O’Brien PC, Palumbo PJ (1993) Hyperlipidemia in Patients With Primary and Secondary Hypothyroidism. Mayo Clin Proc 68:860–866. https://doi.org/10.1016/S0025-6196(12)60694-6
42. Sinha RA, Singh BK, Yen PM (2018) Direct effects of thyroid hormones on hepatic lipid metabolism. Nat Rev Endocrinol 14:259–269. https://doi.org/10.1038/nrendo.2018.10
43. Bakker SJL, ter Maaten JC, Popp-Snijders C et al (2001) The relationship between thyrotropin and low density lipoprotein cholesterol is modified by insulin sensitivity in healthy euthyroid subjects. J Clin Endocrinol Metab 86:1206–1211. https://doi.org/10.1210/jcem.86.3.7324
44. Jung KY, Ahn HY, Han SK et al (2017) Association between thyroid function and lipid profiles, apolipoproteins, and high-density lipoprotein function. J Clin Lipidol 11:1347–1353. https://doi.org/10.1016/j.jacl.2017.08.015

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

Elisa Merchan-Ramirez⁴, Guillermo Sanchez-Delgado⁴, Cristina Arrizabalaga-Arziazu³, Francisco M Acosta⁴,⁵, María Jose Arias-Tellez⁴,⁶, Manuel Muñoz-Torres⁷,⁸,⁹,¹⁰, Jose V Garcia-Lario¹¹, Jose M Llamas-Elvira⁷,¹², Jonatan R Ruiz⁴,¹⁷

1 PROFITTH “PROmoting FITness and Health Through Physical Activity” Research Group, Department of Physical and Sports Education, Sport and Health University Research Institute (iMUDS), Faculty of Sports Science, University of Granada, C/Menéndez Pelayo 32, 18016 Granada, Spain
2 Pennington Biomedical Research Center, Baton Rouge, LA, USA
3 Department of Endocrinology, Fundación Hospital de Jove, Gijón, Spain
4 Turku PET Centre, University of Turku, Turku, Finland
5 Turku PET Centre, Turku University Hospital, Turku, Finland
6 Department of Nutrition, Faculty of Medicine, University of Chile, Santiago, Chile
7 Instituto de Investigación Biosanitaria (Ibs. Granada), Granada, Spain
8 Department of Medicine, University of Granada, Granada, Spain
9 CIBERFES, Instituto de Salud Carlos III, Granada, Spain
10 Endocrinology and Nutrition Service, University Hospital San Cecilio, Granada, Spain
11 UGC Laboratorio Clínico. University Hospital San Cecilio, Granada, Spain
12 Nuclear Medicine Service, “Virgen de Las Nieves” University Hospital, Granada, Spain